Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes

Vaccine

Volumn 24, Issue 35-36, 2006, Pages 6088-6095

  Schulze, Kai ^a   Olive, Colleen ^b   Ebensen, Thomas ^a   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Conjugated vaccines; Diphtheria toxoid; Epitope based vaccines; M protein; SfbI; Streptococcus pyogenes

Indexed keywords

CHOLERA TOXIN B SUBUNIT; DIPHTHERIA VACCINE; EPITOPE; FIBRONECTIN BINDING PROTEIN; M PROTEIN; POLYPEPTIDE; PROTEIN DERIVATIVE; PROTEIN M1; STREPTOCOCCAL FIBRONECTIN BINDING PROTEIN 1; STREPTOCOCCUS VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL SURVIVAL; CONTROLLED STUDY; DRUG CONFORMATION; DRUG CONJUGATION; FEMALE; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL PROTEINS; CHOLERA TOXIN; DIPHTHERIA TOXOID; FEMALE; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MUCUS; SERUM; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; VACCINES, SUBUNIT;

EID: 33746790677     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.024     Document Type: Article

References (69)

1. Hassell M., Fagan P., Carson P., and Currie B.J. Streptococcal necrotising fasciitis from diverse strains of Streptococcus pyogenes in tropical northern Australia: case series and comparison with the literature. BMC Infect Dis 4 (2004) 60
2. Stevens D.L. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 51 (2000) 271-288
3. Stevens D.L. Streptococcal toxic shock syndrome. Clin Microbiol Infect 8 (2002) 133-136
4. Stevens D.L. Group A streptococcal sepsis. Curr Infect Dis Rep 5 (2003) 379-386
5. Ranin L., Opavski N., Djukic S., and Mijac V. Epidemiology of diseases caused by Streptococcus pyogenes in Serbia during a 9-year period. Indian J Med Res 119 Suppl (2004) 155-159
6. Bisno A.L., Brito M.O., and Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 3 (2003) 191-200
7. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13 (2000) 470-511
8. Berrios X., Lagomarsino E., Solar E., Sandoval G., Guzman B., and Riedel I. Post-streptococcal acute glomerulonephritis in Chile-20 years of experience. Pediatr Nephrol 19 (2004) 306-312
9. Martin J.M., Green M., Barbadora K.A., and Wald E.R. Group A streptococci among school-aged children: clinical characteristics and the carrier state. Pediatrics 114 (2004) 1212-1219
10. Gibofsky A., and Zabriskie J.B. Rheumatic fever and poststreptococcal reactive arthritis. Curr Opin Rheumatol 7 (1995) 299-305
11. Group A streptococcal disease: Disease information. Centers for Disease Control and Prevention. Division of Bacterial and Mycotic Diseases; 2004.
12. World Health Report; 1998.
13. Orscheln R.C., Johnson D.R., Olson S.M., et al. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J Infect Dis 191 (2005) 1272-1279
14. Halpern M.T., Schmier J.K., Snyder L.M., et al. Meta-analysis of bacterial resistance to macrolides. J Antimicrob Chemother 55 5 (2005) 748-757
15. Brenciani A., Ojo K.K., Monachetti A., et al. Distribution and molecular analysis of mef(A)-containing elements in tetracycline-susceptible and -resistant Streptococcus pyogenes clinical isolates with efflux-mediated erythromycin resistance. J Antimicrob Chemother 54 (2004) 991-998
16. Szczypa K., Sadowy E., Izdebski R., and Hryniewicz W. A rapid increase in macrolide resistance in Streptococcus pyogenes isolated in Poland during 1996-2002. J Antimicrob Chemother 54 (2004) 828-831
17. Mihaila-Amrouche L., Bouvet A., and Loubinoux J. Clonal spread of emm type 28 isolates of Streptococcus pyogenes that are multiresistant to antibiotics. J Clin Microbiol 42 (2004) 3844-3846
18. Walsh S.R., Ferraro M.J., and Durand M.L. Clindamycin-resistant Streptococcus pyogenes: report of a case. Diag Microbiol Infect Dis 49 (2004) 223-225
19. Dale J.B., Cleary P.P., Fischetti V.A., Kasper D.L., Musser J.M., and Zabriskie J.B. Group A and group B streptococcal vaccine development. A round table presentation. Adv Exp Med Biol 418 (1997) 863-868
20. Cleary P.P., Matsuka Y.V., Huynh T., Lam H., and Olmsted S.B. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 22 (2004) 4332-4341
21. Kapur V., Maffei J.T., Greer R.S., Li L.L., Adams G.J., and Musser J.M. Vaccination with streptococcal extracellular cysteine protease (interleukin-1β conservertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog 16 (1994) 443-450
22. Shet A., Kaplan E., Johnson D., and Cleary P.P. Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections. Indian J Med Res 119 Suppl (2004) 95-98
23. Courtney H.S., Dale J.B., and Hasty D.I. Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infect Immun 64 (1996) 2415-2419
24. Hanski E., and Caparon M. Protein F, a fibronectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci USA 89 (1992) 6172-6176
25. Hanski E., Jaffe J., and Ozeri V. Proteins F1 and F2 of Streptococcus pyogenes. Properties of fibronectin binding. Adv Exp Med Biol 408 (1996) 141-150
26. Kreikemeyer B., Talay S.R., and Chhatwal G.S. Characterization of a novel fibronectin-binding surface protein in group A streptococci. Mol Microbiol 17 (1995) 137-145
27. Rocha C.L., and Fischetti V.A. Identification and characterization of a novel fibronectin-binding protein on the surface of group A streptococci. Infect Immun 67 (1999) 2720-2728
28. Talay S.R., Valentin Weigand P., Jerlstrom P.G., Timmis K.N., and Chhatwal G.S. Fibronectin-binding protein of Streptococcus pyogenes: sequence of the binding domain involved in adherence of streptococci to epithelial cells. Infect Immun 60 (1992) 3837-3844
29. Molinari G., Talay S.R., Valentin Weigand P., Rohde M., and Chhatwal G.S. The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is involved in the internalization of group A streptococci by epithelial cells. Infect Immun 65 (1997) 1357-1363
30. Fischetti V.A. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 2 (1989) 285
31. Robinson J.H., and Kehoe M.A. Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today 13 (1992) 362-367
32. Brandt E.R., Hayman W.A., Currie B., et al. Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol 11 (1999) 569-576
33. Brandt E.R., Hayman W.A., Currie B., Pruksakorn S., and Good M.F. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 15 (1997) 1805-1812
34. Brandt E.R., Teh T., Relf W.A., Hobb R.I., and Good M.F. Protective and nonprotective epitopes from amino termini of M proteins from Australian Aboriginal isolates and reference strains of group A streptococci. Infect Immun 68 (2000) 6587-6594
35. Putz M.M., Ammerlaan W., Schneider F., Jung G., and Muller C.P. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. Vaccine 22 (2004) 4173-4182
36. Wang M.J., Nissen M.H., Buus S., Ropke C., and Claesson M.H. Comparison of CTL reactivity in the spleen and draining lymph nodes after immunization with peptides pulsed on dendritic cells or mixed with Freund's incomplete adjuvant. Immunol Lett 90 (2003) 13-18
37. Sabhnani L., Manocha M., Sridevi K., Shashikiran D., Rayanade R., and Rao D.N. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol Med Microbiol 38 (2003) 215-229
38. Ninomiya A., Ogasawara K., Kajino K., Takada A., and Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20 (2002) 3123-3129
39. Gopal I.N., Quinn A., Henry S.C., Hamilton J.D., Staats H.F., and Frothingham R. Nasal Peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. Microbiol Immunol 49 (2005) 113-119
40. Lomada D., Gambhira R., Nehete P.N., et al. A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine 23 (2004) 555-565
41. Relf W.A., Cooper J., Brandt E.R., et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept Res 9 (1996) 12-20
42. Batzloff M.R., Hayman W.A., Davies M.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 187 (2003) 1598-1608
43. Olive C., Clair T., Yarwood P., and Good M.F. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 20 (2002) 2816-2825
44. Talay S.R., Valentin Weigand P., Timmis K.N., and Chhatwal G.S. Domain structure and conserved epitopes of Sfb protein, the fibronectin-binding adhesin of Streptococcus pyogenes. Mol Microbiol 13 (1994) 531-539
45. Talay S.R., Zock A., Rohde M., et al. Co-operative binding of human fibronectin to Sfbl protein triggers streptococcal invasion into respiratory epithelial cells. Cell Microbiol 2 (2000) 521-535
46. Valentin Weigand P., Talay S.R., Kaufhold A., Timmis K.N., and Chhatwal G.S. The fibronectin binding domain of the Sfb protein adhesin of Streptococcus pyogenes occurs in many group A streptococci and does not cross-react with heart myosin. Microb Pathog 17 (1994) 111-120
47. Guzman C.A., Talay S.R., Molinari G., Medina E., and Chhatwal G.S. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 179 (1999) 901-906
48. Schulze K., Medina E., Talay S.R., Towers R.J., Chhatwal G.S., and Guzman C.A. Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect Immun 69 (2001) 622-625
49. Schulze K., Medina E., Chhatwal G.S., and Guzman C.A. Identification of B- and T-cell epitopes within the fibronectin-binding domain of the SfbI protein of Streptococcus pyogenes. Infect Immun 71 (2003) 7197-7201
50. Hayman W.A., Brandt E.R., Relf W.A., Cooper J., Saul A., and Good M.F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 9 (1997) 1723-1733
51. Borsutzky S., Fiorelli V., Ebensen T., et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 33 (2003) 1548-1556
52. Rharbaoui F., Drabner B., Borsutzky S., et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32 (2002) 2857-2865
53. Medina E., Talay S.R., Chhatwal G.S., and Guzman C.A. Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route. Eur J Immunol 28 (1998) 1069-1077
54. Rheumatic fever and rheumatic heart disease. World Health Org Tech Rep Ser 923 (2004) 1-122
55. Osrin D., Vergnano S., and Costello A. Serious bacterial infections in newborn infants in developing countries. Curr Opin Infect Dis 17 (2004) 217-224
56. McDonald M., Currie B.J., and Carapetis J.R. Acute rheumatic fever: a chink in the chain that links the heart to the throat?. Lancet Infect Dis 4 (2004) 240-245
57. Schulze K., Medina E., Chhatwal G.S., and Guzman C.A. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non-adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine 21 (2003) 1958-1964
58. McMillan D.J., Davies M.R., Good M.F., and Sriprakash K.S. Immune response to superoxide dismutase in group A streptococcal infection. FEMS Immunol Med Microbiol 40 (2004) 249-256
59. Lei B., Liu M., Chesney G.L., and Musser J.M. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis 189 (2004) 79-89
60. Courtney H.S., Hasty D.L., and Dale J.B. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun 71 (2003) 5097-5103
61. Kawabata S., Kunitomo E., Terao Y., et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 69 (2001) 924-930
62. Yang W., Jackson D.C., Zeng Q., and McManus D.P. Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice. Vaccine 19 (2000) 103-113
63. Cruz L.J., Quintana D., Iglesias E., et al. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice. J Pept Sci 6 (2000) 217-224
64. Liu Z., Xiao Y., and Chen Y.H. Epitope-vaccine strategy against HIV-1: today and tomorrow. Immunobiology 208 (2003) 423-428
65. Brandt E.R., Sriprakash K.S., Hobb R.I., et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 6 (2000) 455-459
66. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 (2000) 4778-4782
67. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's Palsy in Switzerland. N Engl J Med 350 (2004) 896-903
68. Williams R.C., and Gibbons R.J. Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal. Science 177 (1972) 697-699
69. Beall B. GenBank Nucleotide Sequence Data Library, accession no. AF077666; 2000